Cargando…

Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy

Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. DCM is a leading cause of mortality in patients with diabetes. We used both in vitro and in vivo experiments to investigate the hypothesis that sophocarpine (SPC), a natural quinolizidine alkaloid derived from a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Fang, Wang, Ling, Liu, Han, Wang, Wei, Hu, Longlong, Xiong, Xiaoying, Wu, Lijuan, Shen, Yunfeng, Yang, Renqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836764/
https://www.ncbi.nlm.nih.gov/pubmed/31736745
http://dx.doi.org/10.3389/fphar.2019.01219
_version_ 1783466967394418688
author Zou, Fang
Wang, Ling
Liu, Han
Wang, Wei
Hu, Longlong
Xiong, Xiaoying
Wu, Lijuan
Shen, Yunfeng
Yang, Renqiang
author_facet Zou, Fang
Wang, Ling
Liu, Han
Wang, Wei
Hu, Longlong
Xiong, Xiaoying
Wu, Lijuan
Shen, Yunfeng
Yang, Renqiang
author_sort Zou, Fang
collection PubMed
description Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. DCM is a leading cause of mortality in patients with diabetes. We used both in vitro and in vivo experiments to investigate the hypothesis that sophocarpine (SPC), a natural quinolizidine alkaloid derived from a Chinese herb, could protect against DCM. We used hyperglycemic myocardial cells and a streptozotocin (STZ)-induced type 1 diabetes mellitus mouse model. SPC protected myocardial cells from hyperglycemia-induced injury by improving mitochondrial function, suppressing inflammation, and inhibiting cardiac apoptosis. The SPC treatment significantly inhibited the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling in high-glucose-stimulated inflammatory responses. Moreover, SPC significantly slowed the development and progression of DCM in STZ-induced diabetic mice. These results show that SPC suppresses NF-κB-mediated inflammation both in vitro and in vivo and may be used to treat DCM.
format Online
Article
Text
id pubmed-6836764
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68367642019-11-15 Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy Zou, Fang Wang, Ling Liu, Han Wang, Wei Hu, Longlong Xiong, Xiaoying Wu, Lijuan Shen, Yunfeng Yang, Renqiang Front Pharmacol Pharmacology Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. DCM is a leading cause of mortality in patients with diabetes. We used both in vitro and in vivo experiments to investigate the hypothesis that sophocarpine (SPC), a natural quinolizidine alkaloid derived from a Chinese herb, could protect against DCM. We used hyperglycemic myocardial cells and a streptozotocin (STZ)-induced type 1 diabetes mellitus mouse model. SPC protected myocardial cells from hyperglycemia-induced injury by improving mitochondrial function, suppressing inflammation, and inhibiting cardiac apoptosis. The SPC treatment significantly inhibited the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling in high-glucose-stimulated inflammatory responses. Moreover, SPC significantly slowed the development and progression of DCM in STZ-induced diabetic mice. These results show that SPC suppresses NF-κB-mediated inflammation both in vitro and in vivo and may be used to treat DCM. Frontiers Media S.A. 2019-10-31 /pmc/articles/PMC6836764/ /pubmed/31736745 http://dx.doi.org/10.3389/fphar.2019.01219 Text en Copyright © 2019 Zou, Wang, Liu, Wang, Hu, Xiong, Wu, Shen and Yang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zou, Fang
Wang, Ling
Liu, Han
Wang, Wei
Hu, Longlong
Xiong, Xiaoying
Wu, Lijuan
Shen, Yunfeng
Yang, Renqiang
Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_full Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_fullStr Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_full_unstemmed Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_short Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_sort sophocarpine suppresses nf-κb-mediated inflammation both in vitro and in vivo and inhibits diabetic cardiomyopathy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836764/
https://www.ncbi.nlm.nih.gov/pubmed/31736745
http://dx.doi.org/10.3389/fphar.2019.01219
work_keys_str_mv AT zoufang sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
AT wangling sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
AT liuhan sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
AT wangwei sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
AT hulonglong sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
AT xiongxiaoying sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
AT wulijuan sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
AT shenyunfeng sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
AT yangrenqiang sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy